BRAF and uveal melanoma: Thus, mutually exclusive oncogenic mutations in melanoma involving B Rapidly Accelerated Fibrosarcoma (BRAF) (about 50%), Neuroblastoma Rapidly Accelerated Sarcoma (NRAS) (about 15–20%), c-Kit (about 2%), and Guanine Nucleotide -binding Protein G(q) subunit alpha/Guanine Nucleotide -binding Protein G subunit alpha 11 (GNAQ/GNA11) (about 50% of uveal melanoma) have been identified [11].